Dr. Edwin P. Alyea

Dr. Edwin P. Alyea ay dalubhasa sa paggamot sa mga pasyente ng kanser sa dugo na isinasaalang-alang ang stem cell o bone marrow transplant. Sa nakalipas na 20 taon, nagkaroon ng malaking pagsulong sa paglipat, na nagresulta sa mas mahusay na mga resulta. Kasama sa mga pagsulong na ito ang kakayahang gumamit ng mas mababang mga dosis ng chemotherapy upang bawasan ang toxicity sa mga pasyente, pati na rin ang mga paraan upang mabawasan ang posibilidad ng pagbabalik. Interesado ako sa paggamit ng mga nobelang gamot at diskarte upang mapabuti ang mga kinalabasan pagkatapos ng stem cell transplant para sa mga malignancies sa dugo. Mahalagang makipagtulungan sa mga pasyente upang tukuyin ang kanilang mga layunin sa paggamot at ang pinakamahusay na paraan ng pagkilos. Sa loob ng maraming taon pagkatapos ng kanilang transplant, gustung-gusto kong magtrabaho kasama ang mga pasyente at kanilang mga pamilya.

Sertipikasyon ng Lupon

American Board of Internal Med, Medical Oncology

pagsasama

Medical Oncology, Dana-Farber Cancer Institute (Massachusetts), 1992-1995

Residensya

Internal Medicine, Brigham at Women's Hospital (Massachusetts), 1989-1992

Edukasyon

MD, Duke University, 1989

• Pang-adultong Bone Marrow at Stem Cell Transplant
• Autologous Transplant
• Allogeneic Transplant
• Syngeneic Transplant

• Hourigan, Christopher S., Laura W. Dillon, Gege Gui, Brent R. Logan, Mingwei Fei, Jack Ghannam, Yuesheng Li, et al. “Impact of Conditioning Intensity of Allogeneic Transplantation for Talamak na Myeloid Leukemia With Genomic Evidence of Residual Disease.” J Clin Oncol 38, hindi. 12 (Abril 20, 2020): 1273–83. https://doi.org/10.1200/JCO.19.03011.
• Soiffer, Robert J., Haesook T. Kim, Joseph McGuirk, Mitchell E. Horwitz, Laura Johnston, Mrinal M. Patnaik, Witold Rybka, et al. “Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.” J Clin Oncol 35, hindi. 36 (Disyembre 20, 2017): 4003–11. https://doi.org/10.1200/JCO.2017.75.8177.
• Liu, Hien Duong, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani, Taiga Nishihori, Baldeep Wirk, Amer Beitinjaneh, et al. “Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.” Biol Blood Marrow Transplant 23, hindi. 5 (Mayo 2017): 767–75. https://doi.org/10.1016/j.bbmt.2017.01.078.
• Scott, Bart L., Marcelo C. Pasquini, Brent R. Logan, Juan Wu, Steven M. Devine, David L. Porter, Richard T. Maziarz, et al. “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Mga sindrom.” J Clin Oncol 35, hindi. 11 (Abril 10, 2017): 1154–61. https://doi.org/10.1200/JCO.2016.70.7091.
• Shaffer, Brian C., Kwang Woo Ahn, Zhen-Huan Hu, Taiga Nishihori, Adriana K. Malone, David Valcárcel, Michael R. Grunwald, et al. “Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.” J Clin Oncol 34, hindi. 16 (Hunyo 1, 2016): 1864–71. https://doi.org/10.1200/JCO.2015.65.0515.
• Devine, Steven M., Kouros Owzar, William Blum, Flora Mulkey, Richard M. Stone, Jack W. Hsu, Richard E. Champlin, et al. “Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.” J Clin Oncol 33, hindi. 35 (Disyembre 10, 2015): 4167–75. https://doi.org/10.1200/JCO.2015.62.7273.
• Jacobson, Caron A., Lixian Sun, Haesook T. Kim, Sean M. McDonough, Carol G. Reynolds, Michael Schowalter, John Koreth, et al. “Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.” Biol Blood Marrow Transplant 20, hindi. 5 (Mayo 2014): 668–75. https://doi.org/10.1016/j.bbmt.2014.01.021.
• Cutler, Corey, Haesook T. Kim, Bhavjot Bindra, Stefanie Sarantopoulos, Vincent T. Ho, Yi-Bin Chen, Jacalyn Rosenblatt, et al. “Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.” Dugo 122, hindi. 8 (Agosto 22, 2013): 1510–17. https://doi.org/10.1182/blood-2013-04-495895.
• Porcheray, Fabrice, David B. Miklos, Blair H. Floyd, Stefanie Sarantopoulos, Roberto Bellucci, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea, Jerome Ritz, and Emmanuel Zorn. “Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation.” paglipat 92, hindi. 3 (Agosto 15, 2011): 359–65. https://doi.org/10.1097/TP.0b013e3182244cc3.